Literature DB >> 12595550

Identification of the ATP-binding site in the terminase subunit pUL56 of human cytomegalovirus.

Brigitte Scholz1, Sabine Rechter, John C Drach, Leroy B Townsend, Elke Bogner.   

Abstract

Human cytomegalovirus (HCMV) terminase is composed of subunits pUL56 (130 kDa) and pUL89 ( approximately 75 kDa), encoded by the UL56 and UL89 genes. In a recent investigation, we demonstrated that the main ATPase activity is associated with the large terminase subunit pUL56. The protein has two putative ATP-binding sites, which were suggested to be composed of the sequence (amino acids 463-470) for ATP-binding site 1 and YNETFGKQ (amino acids 709-716) for the second site. We now demonstrate using a 1.5 kb fragment encoding the C-terminal half of pUL56 that ATP-binding site 1 is not critical for the function, whereas ATP-binding site 2 is required for the enzymatic activity. Mutation G714A in this protein reduced the ATPase activity to approximately 65% and the double mutation G714A/K715N showed a reduction up to 75%. However, the substitution of E711A revoked the effect of the substitutions. The functional character of the ATP-binding site was demonstrated by transfer of YNETFGKQLSIACLR (709-723) to glutathione-S-transferase (GST). Interestingly, vanadate, an ATPase inhibitor, has the ability to block the ATPase activity of pUL56 as well as of Apyrase, while the antitumor ATP-mimetic agent geldanamycin, did not affect the ATP-binding of pUL56. Furthermore, in contrast to an inactive control compound, the specific HCMV terminase inhibitor BDCRB showed a partial inhibition of the pUL56-specific ATPase activity. Our results clearly demonstrated that (i) the enzymatic activity of the terminase subunit pUL56 could be inhibited by vanadate, (ii) only the ATP-binding site 2 is critical for the pUL56 function and (iii) glycine G714 is an invariant amino acid.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12595550      PMCID: PMC149822          DOI: 10.1093/nar/gkg229

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  39 in total

1.  Visualization of the maturation transition in bacteriophage P22 by electron cryomicroscopy.

Authors:  Z Zhang; B Greene; P A Thuman-Commike; J Jakana; P E Prevelige; J King; W Chiu
Journal:  J Mol Biol       Date:  2000-03-31       Impact factor: 5.469

2.  Herpes simplex virus DNA packaging sequences adopt novel structures that are specifically recognized by a component of the cleavage and packaging machinery.

Authors:  K Adelman; B Salmon; J D Baines
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

3.  ATPase activity of the terminase subunit pUL56 of human cytomegalovirus.

Authors:  Jae-Seon Hwang; Elke Bogner
Journal:  J Biol Chem       Date:  2001-12-13       Impact factor: 5.157

4.  The N-terminal ATPase site in the large terminase protein gp17 is critically required for DNA packaging in bacteriophage T4.

Authors:  V B Rao; M S Mitchell
Journal:  J Mol Biol       Date:  2001-11-30       Impact factor: 5.469

5.  ATPase center of bacteriophage lambda terminase involved in post-cleavage stages of DNA packaging: identification of ATP-interactive amino acids.

Authors:  J Q Hang; B F Tack; M Feiss
Journal:  J Mol Biol       Date:  2000-09-29       Impact factor: 5.469

6.  Isolation of a potent (Na-K)ATPase inhibitor from striated muscle.

Authors:  L Josephson; L C Cantley
Journal:  Biochemistry       Date:  1977-10-18       Impact factor: 3.162

7.  Alteration by site-directed mutagenesis of the conserved lysine residue in the ATP-binding consensus sequence of the RecD subunit of the Escherichia coli RecBCD enzyme.

Authors:  F Korangy; D A Julin
Journal:  J Biol Chem       Date:  1992-01-25       Impact factor: 5.157

8.  The terminase subunits pUL56 and pUL89 of human cytomegalovirus are DNA-metabolizing proteins with toroidal structure.

Authors:  Hanno Scheffczik; Christos G W Savva; Andreas Holzenburg; Larissa Kolesnikova; Elke Bogner
Journal:  Nucleic Acids Res       Date:  2002-04-01       Impact factor: 16.971

Review 9.  Benzimidazole nucleosides, nucleotides, and related derivatives.

Authors:  L B Townsend; G R Revankar
Journal:  Chem Rev       Date:  1970-06       Impact factor: 60.622

Review 10.  DNA packaging by the double-stranded DNA bacteriophages.

Authors:  W C Earnshaw; S R Casjens
Journal:  Cell       Date:  1980-09       Impact factor: 41.582

View more
  30 in total

1.  Intracellular Distribution of Capsid-Associated pUL77 of Human Cytomegalovirus and Interactions with Packaging Proteins and pUL93.

Authors:  Pánja Köppen-Rung; Alexandra Dittmer; Elke Bogner
Journal:  J Virol       Date:  2016-06-10       Impact factor: 5.103

2.  Host protein Snapin interacts with human cytomegalovirus pUL130 and affects viral DNA replication.

Authors:  Guili Wang; Gaowei Ren; Xin Cui; Zhitao Lu; Yanpin Ma; Ying Qi; Yujing Huang; Zhongyang Liu; Zhengrong Sun; Qiang Ruan
Journal:  J Biosci       Date:  2016-06       Impact factor: 1.826

3.  Human cytomegalovirus resistance to deoxyribosylindole nucleosides maps to a transversion mutation in the terminase subunit-encoding gene UL89.

Authors:  Brian G Gentry; Quang Phan; Ellie D Hall; Julie M Breitenbach; Katherine Z Borysko; Jeremy P Kamil; Leroy B Townsend; John C Drach
Journal:  Antimicrob Agents Chemother       Date:  2014-10-27       Impact factor: 5.191

4.  Interaction of the putative human cytomegalovirus portal protein pUL104 with the large terminase subunit pUL56 and its inhibition by benzimidazole-D-ribonucleosides.

Authors:  Alexandra Dittmer; John C Drach; Leroy B Townsend; Anke Fischer; Elke Bogner
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

5.  Impact of 2-bromo-5,6-dichloro-1-beta-D-ribofuranosyl benzimidazole riboside and inhibitors of DNA, RNA, and protein synthesis on human cytomegalovirus genome maturation.

Authors:  Michael A McVoy; Daniel E Nixon
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

6.  Epstein-Barr virus BALF3 has nuclease activity and mediates mature virion production during the lytic cycle.

Authors:  Shih-Hsin Chiu; Meng-Chuan Wu; Chung-Chun Wu; Yu-Ching Chen; Su-Fang Lin; John T-A Hsu; Chung-Shi Yang; Ching-Hwa Tsai; Kenzo Takada; Mei-Ru Chen; Jen-Yang Chen
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

7.  Inhibition of human cytomegalovirus replication by benzimidazole nucleosides involves three distinct mechanisms.

Authors:  David L Evers; Gloria Komazin; Roger G Ptak; Dongjin Shin; Brian T Emmer; Leroy B Townsend; John C Drach
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

8.  Susceptibilities of human cytomegalovirus clinical isolates and other herpesviruses to new acetylated, tetrahalogenated benzimidazole D-ribonucleosides.

Authors:  Jae-Seon Hwang; Rita Schilf; John C Drach; Leroy B Townsend; Elke Bogner
Journal:  Antimicrob Agents Chemother       Date:  2009-09-28       Impact factor: 5.191

9.  1-Isopropyl-4-nitro-6-meth-oxy-1H-benzimidazole.

Authors:  Michael D Moore; Prashi Jain; Patrick T Flaherty; Peter L D Wildfong
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2008-06-25

10.  Mechanism of action of the ribopyranoside benzimidazole GW275175X against human cytomegalovirus.

Authors:  Mark R Underwood; Robert G Ferris; Dean W Selleseth; Michelle G Davis; John C Drach; Leroy B Townsend; Karen K Biron; F Leslie Boyd
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.